Lack of exercise and consumption of spicy food will significantly increase the demand for irritable bowel syndrome with diarrhea market
The global irritable bowel syndrome with diarrhea market is rising at a significant pace, projected to rise at a CAGR of 11.3% during the estimated period from 2022 to 2030.Recent approvals for two new prescription drugs to treat irritable bowel syndrome with diarrhea (IBS-D) have become the biggest phenomenon in the IBS-D drugs market. These approvals are viewed as a breakthrough step in the long struggle to discover an effective treatment for IBS-D.
Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora. Xifaxan had been used off-label for treating IBS-D, thus direct approval for treating IBS-D will lead to growth in demand for Xifaxan during the forecast period. Drugs such as loperamide will experience a slack in demand due to the introduction of the said novel drugs.
In addition, lockdown restrictions and the need to maintain social distancing due to the ongoing COVID-19 pandemic have resulted in more number of people staying at home. Hence, a sedentary lifestyle has resulted in the development of irritable bowel syndrome. In addition, increasing demand for spicy food drastically alters the bowel peristaltic activity causing fluid stool, thereby the irritable bowel syndrome with Diarrhea market is expected to witness significant growth during the forecast period from 2022 to 2030.
Increasing demand for spicy food will boost the market growth in North America;
Geographically, North America is the largest market for IBS-D drugs. Higher awareness about the disease, expected prompt availability of the newly approved drugs, better reimbursement system, and higher IBS prevalence are the prime factors that drive the IBS-D drugs market in North America. On the other hand, Asia Pacific is expected to be the fastest-growing regional market for IBS-D drugs. Japan with its largest pool of geriatric population and with the approval for Xifaxan makes the country the largest national market in the Asia Pacific region. In addition, it is also estimated that factors such as moderate purchasing power in the patient population, lower diagnosis rates, and poor disease awareness will contribute to sustained demand for OTC IBS-D drugs in the region. Regions such as Latin America and MENA are believed to follow the trends in Europe and North American markets.This report is a comprehensive research study of the global irritable bowel syndrome with diarrhea market that elaborates the major trends in the market based on quantitative and qualitative research. This report provides a detailed description of global irritable bowel syndrome with diarrhea market segmenting the market by drug types and geography. This report aids the market stakeholders to make improved decisions and strategies in the irritable bowel syndrome with diarrhea market.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Irritable Bowel Syndrome with Diarrhea market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Irritable Bowel Syndrome with Diarrhea market and their expected impact during the forecast period.
Market Segmentation
Drugs
- Eluxadoline
- Alosetron
- Rifaximin
- Loperamide
- Diphenoxylate + Atropine
- Dicyclomine and Hyoscyamine
- Pipeline Drug Analysis
Prescription Type
- Prescribed and OTC Drugs
- Prescribed Branded and Prescribed Generic Drugs
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Irritable Bowel Syndrome with Diarrhea market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Irritable Bowel Syndrome with Diarrhea market?
- Which is the largest regional market for Irritable Bowel Syndrome with Diarrhea market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Irritable Bowel Syndrome with Diarrhea market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Irritable Bowel Syndrome with Diarrhea market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Irritable Bowel Syndrome with Diarrhea Market
2.2. Global Irritable Bowel Syndrome with Diarrhea Market, By Drugs, 2021 (US$ Million)
2.3. Global Irritable Bowel Syndrome with Diarrhea Market, By Prescription Type, 2021 (US$ Million)
2.4. Global Irritable Bowel Syndrome with Diarrhea Market, By Geography, 2021 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2021
3. Irritable Bowel Syndrome with Diarrhea Market: Competitive Analysis
3.1. Market Positioning of Key Irritable Bowel Syndrome with Diarrhea Market Vendors
3.2. Strategies Adopted by Irritable Bowel Syndrome with Diarrhea Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Irritable Bowel Syndrome with Diarrhea Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Irritable Bowel Syndrome with Diarrhea Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Eluxadoline
5.3.2. Alosetron
5.3.3. Rifaximin
5.3.4. Loperamide
5.3.5. Diphenoxylate + Atropine
5.3.6. Dicyclomine and Hyoscyamine
5.3.7. Pipeline Drug Analysis
6. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Prescribed and OTC Drugs
6.3.2. Prescribed Branded and Prescribed Generic Drugs
7. North America Irritable Bowel Syndrome with Diarrhea Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
7.3. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
7.4.Irritable Bowel Syndrome with Diarrhea Market: By Region, 2020-2030, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
7.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
7.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
7.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
8. UK and European Union Irritable Bowel Syndrome with Diarrhea Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
8.3. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
8.4.Irritable Bowel Syndrome with Diarrhea Market: By Region, 2020-2030, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
8.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
8.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
8.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
8.4.1.4.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
8.4.1.5. France
8.4.1.5.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
8.4.1.5.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
8.4.1.6.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
9. Asia Pacific Irritable Bowel Syndrome with Diarrhea Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
9.3. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
9.4.Irritable Bowel Syndrome with Diarrhea Market: By Region, 2020-2030, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
9.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
9.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
9.4.1.3. India
9.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
9.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
9.4.1.4.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
9.4.1.5.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
9.4.1.6.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
10. Latin America Irritable Bowel Syndrome with Diarrhea Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
10.3. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
10.4.Irritable Bowel Syndrome with Diarrhea Market: By Region, 2020-2030, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
10.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
10.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
10.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
11. Middle East and Africa Irritable Bowel Syndrome with Diarrhea Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
11.3. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
11.4.Irritable Bowel Syndrome with Diarrhea Market: By Region, 2020-2030, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
11.4.1.1.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
11.4.1.2.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Drugs, 2020-2030, USD (Million)
11.4.1.3.1. Irritable Bowel Syndrome with Diarrhea Market: By Prescription Type, 2020-2030, USD (Million)
12. Company Profile
12.1. Astellas Pharmaceuticals
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Actavis
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Pfizer
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. GlaxoSmithKline
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Salix Pharmaceuticals Ltd
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. AstraZenenca
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
List of Figures
Figure 1 Global Irritable Bowel Syndrome with Diarrhea Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Irritable Bowel Syndrome with Diarrhea Market: Quality Assurance
Figure 5 Global Irritable Bowel Syndrome with Diarrhea Market, By Drugs, 2021
Figure 6 Global Irritable Bowel Syndrome with Diarrhea Market, By Prescription Type, 2021
Figure 7 Global Irritable Bowel Syndrome with Diarrhea Market, By Geography, 2021
Figure 8 Market Geographical Opportunity Matrix - Global Irritable Bowel Syndrome with Diarrhea Market, 2021
Figure 9 Market Positioning of Key Irritable Bowel Syndrome with Diarrhea Market Players, 2021
Figure 10 Global Irritable Bowel Syndrome with Diarrhea Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 11 Global Irritable Bowel Syndrome with Diarrhea Market, By Drugs, 2021 Vs 2030, %
Figure 12 Global Irritable Bowel Syndrome with Diarrhea Market, By Prescription Type, 2021 Vs 2030, %
Figure 13 U.S. Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 14 Canada Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 15 Rest of North America Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 16 UK Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 17 Germany Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 18 Spain Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 19 Italy Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 20 France Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 21 Rest of Europe Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 22 China Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 23 Japan Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 24 India Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 25 Australia Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 26 South Korea Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 27 Rest of Asia Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 28 Brazil Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 29 Mexico Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 30 Rest of Latin America Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 31 GCC Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 32 Africa Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
Figure 33 Rest of Middle East and Africa Irritable Bowel Syndrome with Diarrhea Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 2 Global Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 3 North America Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 4 North America Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 5 U.S. Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 6 U.S. Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 7 Canada Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 8 Canada Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 9 Rest of North America Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 10 Rest of North America Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 11 UK and European Union Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 12 UK and European Union Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 13 UK Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 14 UK Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 15 Germany Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 16 Germany Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 17 Spain Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 18 Spain Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 19 Italy Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 20 Italy Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 21 France Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 22 France Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 23 Rest of Europe Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 24 Rest of Europe Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 25 Asia Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 26 Asia Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 27 China Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 28 China Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 29 Japan Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 30 Japan Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 31 India Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 32 India Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 33 Australia Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 34 Australia Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 35 South Korea Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 36 South Korea Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 37 Latin America Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 38 Latin America Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 39 Brazil Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 40 Brazil Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 41 Mexico Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 42 Mexico Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 43 Rest of Latin America Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 44 Rest of Latin America Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 45 Middle East and Africa Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 46 Middle East and Africa Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 47 GCC Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 48 GCC Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 49 Africa Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 50 Africa Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Table 51 Rest of Middle East and Africa Irritable Bowel Syndrome with Diarrhea Market By Drugs, 2020-2030, USD (Million)
Table 52 Rest of Middle East and Africa Irritable Bowel Syndrome with Diarrhea Market By Prescription Type, 2020-2030, USD (Million)
Companies Mentioned
- Astellas Pharmaceuticals
- Actavis
- Pfizer
- GlaxoSmithKline
- Salix Pharmaceuticals Ltd
- AstraZenenca
